Gadobenate has been safely used in infants, so it does not appear to pose a substantial risk to a breastfed infant.[1] Guidelines developed by North American professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[2-4]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Fraum TJ, Ludwig DR, Bashir MR, et al. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging 2017;46:338-53. [PubMed: 28083913]
2.
Copel J, El-Sayed Y, Heine RP, et al. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol 2017;130:e210-e6. [PubMed: 28937575]
3.
American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2023;Version 2023:120-1. https://www.acr.org/Clinical-Resources/Contrast-Manual
4.
Bookwalter CA, McDonald RJ, Packard AT, et al. Contrast media in pregnant and lactating patients, from the AJR special series on contrast media. AJR Am J Roentgenol 2024. [PubMed: 39046138]
Substance Identification
Substance Name
Gadobenate
CAS Registry Number
113662-23-0
Drug Class
Breast Feeding
Lactation
Milk, Human
Contrast Media
Diagnostic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
